All News
Filter News
Found 10,056 articles
-
First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
12/8/2019
Regeneron Pharmaceuticals, Inc. announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma.
-
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
12/7/2019
Oncopeptides AB will present follow-up data from the pivotal Phase 2 HORIZON study at the ASH Annual Meeting 2019.
-
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
12/7/2019
Oral Presentation at the American Society of Hematology (ASH) Annual Meeting on December 7, 2019
-
Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology
12/7/2019
Five Patients were included in the analysis; all five patients showed clinical improvement in as early as two weeks
-
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
12/7/2019
Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)
-
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
12/7/2019
Data from the pivotal liso-cel TRANSCEND NHL 001 study demonstrate patients with relapsed/refractory large B-cell lymphomas experienced high rate of durable responses
-
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition
12/7/2019
99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment
-
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
12/6/2019
The American Society of Hematology (ASH) today released the most comprehensive set of recommendations to date aimed at establishing uniformity and global standards for clinical trial endpoints used to evaluate new therapies for sickle cell disease (SCD).
-
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
12/6/2019
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug Administration (FDA) that Reblozyl (luspatercept-aamt) will not be reviewed at the Oncologic Drugs Advisory Committee (“ODAC”) meeting scheduled for December 18, 2019.
-
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
12/6/2019
Bristol-Myers Squibb Company (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced positive top-line results from KarMMa, a pivotal, open-label, single arm, multicenter, Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121).
-
Multiple Myeloma Research Foundation (MMRF) Continues to Accelerate Discoveries and Breakthroughs
12/6/2019
The Multiple Myeloma Research Foundation (MMRF) today announced that 34 abstracts will be presented at the 61st American Society of Hematology Annual Meeting in Orlando from December 7-10.
-
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma
12/6/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in previously treated patients with multiple myeloma.
-
The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments
12/6/2019
The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS's unique free service providing clinical trials navigation and support to blood cancer patients and their families
-
Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting
12/6/2019
Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide an update regarding the data presented December 7-8 at the American Society Hematology (ASH) Annual Meeting 2019.
-
Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
12/6/2019
Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral presentation of ELZONRIS clinical data in myelofibrosis, at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, that is being held from December 7-10 in Orlando, FL.
-
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer
12/6/2019
Stemline Therapeutics, Inc. announced the appointment of Robert M. Francomano as Chief Commercial Officer.
-
EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting
12/5/2019
EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands.
-
Cerecor to Acquire Aevi Genomic Medicine
12/5/2019
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger agreement to acquire Aevi Genomic Medicine
-
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and Exposition
12/5/2019
Top researchers will present abstracts on latest clinical research advancing cancer treatment options
-
Cancer Treatment Centers of America Continues Pioneering Efforts in Immuno-Oncology; Doses First Patient in Novel Immunotherapy Clinical Trial
12/5/2019
Investigational medicine NKTR-255 being evaluated for safety and tolerability as monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma and in combination with multiple targeted antibodies in multiple myeloma